. Author manuscript; available in PMC: 2013 Jan 29.

Published in final edited form as: Mol Pharm. 2009 May-Jun;6(3):747–751. doi: 10.1021/mp800194y

Table 1.

Luciferase gene knockdown with 3′-biotinyl siRNA targeted with the HIRMAb/SA delivery system

Treatment	luciferase activity (pg/mg protein)
Treatment	24 hours	48 hours
Control	402 ± 8	1452 ± 10
Biotinyl siRNA	370 ± 16	1347 ± 57
Biotinyl siRNA plus SA	394 ± 30	1281 ± 15
Biotinyl siRNA plus HIRMAb/SA	73 ± 6^†	97 ± 29^†

Mean ± SE (n=4 dishes/point). The medium concentration of biotinyl siRNA, the SA, and the HIRMAb/SA was 115 nM, 200 nM, and 400 nM, respectively.

^†

p<0.01 difference from control (ANOVA).